this study was to explore whether particular PsA subtypes are associated with an increased cardiovascular risk. Methods: 100 patients with PsA attending the University Hospital of Wales were asked to complete a questionnaire about their cardiovascular risk factors. Anthropometric and biochemical measurements, including BP, BMI, CRP and cholesterol, were also recorded. Patients were grouped into one of the five PsA subtypes as described by Moll and Wright. QRISK2 scores were then used to determine the 10-year risk of developing CVD. Multivariate analyses using linear and logistic regression with QRISK2 score and QRISK2 score >10% as dependent variables were conducted and adjusted for known cardiovascular risk factors. Results: Symmetrical polyarthritis was the most common subtype, no patients had arthritis mutilans. There were no statistically significant differences between the subtypes with regards to age, gender, BMI, blood pressure, smoking status, and cholesterol, ESR or CRP. Statistically significant differences were found between the subtypes for presence of existing CVD and diabetes mellitus with p-values of 0.004 and 0.045 respectively using Chi-square (X2) tests. The proportion of patients with QRISK2 score >10% was also found to be different between the various subtypes, almost reaching statistical significance with a p-value of 0.056. 
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